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Summary 
New insights into HIV-pathogenesis suggest that the cell mediated immune response might play a 
crucial role in controlling HIV infection by suppressing HIV-replication in CD4-positive cells by 
a lymphokine-like soluble factor and by killing HIV-infected cells via classical CTL mediated ly-
sis. This type of a cellular immune response rather than an antibody response seems to be most pro-
mising to protect if not from infection, so at least from disease. Therefore rationally designed candi-
date vaccines should be capable of inducing a cell mediated immunity in addition to a humoral im-
mune response. In order to avoid adverse side effects upon immunization, carefully selected anti-
gens and epitopes should be presented in a favourable manner to the immune system. In previous 
experiments, we could demonstrate that the %%%-polyprotein precursor, known to include a series 
of T-helper and CTL epitopes, assembles to highly immunogenic, complete noninfectious HIV-1 
virus-like particles (VLP). Based on these VLP we developed a novel antigen presentation system, 
which allows the presentation of selected epitopes derived from HIV reading frames other than 
gag to the immune system. Alternatively complete derivatives of the HIV-1 external glycoprotein 
can be presented by the VLP. Immunological analysis of different VLP preparations in a BALB/c 
mouse model revealed the induction of a strong CTL response. The significance of these observa-
tions for future vaccine strategies is discussed. 
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Introduction 
The paradigm of a rational vaccine design is the 
development of the recombinant hepatitis-B-
virus vaccine by inducing high titers of virus 
neutralizing antibodies towards structures ex-
posed on the surface of the virion. In analogy, 
H I V vaccine development focused for the last 
decade primarily on the induction of high t i -
ters of neutralizing antibodies to a recombi-
nant H I V - 1 envelope glycoprotein (rgpl20) in 
order to achieve a broad sterilizing immunity. 
However, large-scale phase III field trials for 
testing of two different rgpl20 candidate vac-
cines have been judged by the A R A C (AIDS 
Research Advisory Committee) not to be very 
promising and therefore have been put on ice 
(Macilwain, 1994). One of the reasons for the 
failure of this approach is certainly the low 
complexity and high variability of these vac-
cine preparations in addition to their inability 
to induce a strong C T L response. 
Although the precise role of HIV-specific 
C T L s in infected individuals is not completely 
clear to date, there is ample evidence that a 
shift from a T^-predominant pattern of cyto-
kine production (IL-2; IFN-y) stimulating the 
cell mediated immune response to a T ^ - p r e -
dominant phenotype (IL-4, IL-10) clearly cor-
relates with disease progression towards A I D S 
(Amadori et al., 1992; Clerici et al., 1993a, b ; 
Sher et al., 1992). This hypothesis is consistent 
with recent observations demonstrating high 
levels of T H 1 cells and an intact C T L response 
in long term survivors and confirmes data ob-
tained for a series of individuals at risk who 
have been exposed to H I V without showing 
any signs of infection {Rowland et al., 1992). 
Dr. Levy and his group demonstrated in a se-
ries of excellent experiments, that C D 8 posi-
tive cells with previous contact to H I V antigen 
secrete a soluble lymphokine-like factor that 
supresses H I V replication in infected cells. 
According to very recent data, this effect 
seems to be especially strong within the group 
of long term non progressors (Walker et al., 
1986, 1989a, b). In African green monkeys 
(Agm), the natural host of simian immunode-
ficiency virus (SIV), a suppressive factor exhi-
biting identical properties has been reported 
by Dr. Ennen and coworkers, which is sup-
posed to be responsible for the control of SIV 
in A g m {Ennen et al., 1994). In addition, long 
term non progressors seem to recognize a 
variety of different C T L epitopes allready 
early during H I V infection whereas indi-
viduals progressing to disease demonstrated a 
very weak C T L response needing extensive 
in vitro restimulation (Dr. T. Harrer, Erlangen, 
pers. communication). 
Therefore one of the key issues in the develop-
ing future HIV-candidate vaccines is to induce 
a strong cell mediated in addition to a humoral 
immune response towards a complex and, if 
possible, conserved antigen "cocktail". In or-
der to meet these requirements novel antigen 
presentation systems need to be designed. A 
series of different formulations have been de-
vised in the past in order to achieve favourable 
antigen presentation ranging from replicating 
vectors, lipopeptides to particulate carrier 
molecules. Induction of a strong immune re-
sponse in absence of adjuvants by particulate 
structures has been suggested by several 
groups including ourselves. Based on the he-
patitis B virus 22 nm lipoprotein particles, the 
H B V core particles or by the yeast transposon 
T Y - A gene a number of heterologous antigen 
presentation systems have been designed al-
lowing the induction of humoral and cellular 
immune responses to short "foreign" peptides 
presented by the particulate carrier {Michel et 
al., 1990; Ullrich et a l , 1992; Schlienger et a l , 
1992; Kingsman and Kingsman, 1988). H o w -
ever, in order to induce protective immune re-
sponses to highly variable viruses, the presen-
tation of complex antigens containing a series 
of conserved B- and T-cell epitopes w i l l be re-
quired to restrict immunological escape and to 
achieve synergistic effects upon immuniza-
tion. 
Results and Discussion 
As reported previously, the H I V group spe-
cific antigen Pr55 g* g includes all requirements 
for the formation of immature H I V virions 
{Gheysen et a l , 1989; Wagner et al., 1992a). 
The Pr55 g* g molecules are synthesized on free 
ribosomes and accumulate at the inner side of 
the plasma membrane where they form the i m -
mature viral particle that is released from the 
cell by budding. However, the H I V - 1 Pr55 g" g 
polyprotein precursor is not only the catalyst 
of viral assembly but seems to play a key role in 
the control of disease progression by including 
a number of T-helper and cytotoxic T-cell 
( C T L ) epitopes. In the context of recent stud-
ies on long term survivors there is increasing 
evidence, that cell mediated immunity towards 
conserved epitopes and reading frames includ-
ing the gtfg-gene product might correlate with 
an extended asymptomatic phase or even com-
plete control of the disease. These considera-
tions prompted us to investigate the possibility 
of constructing a novel, noninfectious and per 
se highly immunogenic antigen presentation 
system on the basis of Pr55 g* g virus-like par-
ticles (VLP) {Wagner et al., 1991). However, to 
extend the immunogenic potential of the auto-
logous gag-VLPs, two different concepts have 
been elaborated (Fig. 1). Construction of these 
V L P s and immunogenicity studies have been 
performed as follows: 
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Fig. 1: Pr55g4g VLPs: A n universal principle of selective antigen presentation. Schematic overview of two different con-
cepts to extend the particulate carrier system by immunologically relevant epitopes or conformational structures. (A) Im-
munologically relevant, well characterized epitopes (black squiggles) for example from the HIV-1 external envelope gly-
coprotein gpl20 were inserted into mutant gag polypeptides to replace the deleted sequences or fused to the Pr55g*g poly-
peptide to generate carboxy-terminal fusion proteins. (B) Chimeric, modified gpl20 constructs were stably anchored on 
the surface of the Pr55g"g particle by a heterologous transmembrane domain. Epitopes, suggested to be assotiated with ad-
verse side effects (white squiggles) are excluded. 
"Foreign" epitopes inserted into chimeric VLPs 
This concept follows the construction of 
Pr55 g* g expression cassetts allowing the inser-
tion of carefully selected epitopes from H I V 
reading frames other than gag. Resulting chi-
meric proteins should assemble into prema-
ture V L P when expressed in eucaryotic cells 
which results in the presentation of additional 
imunologically relevant epitopes. This concept 
also allowes to exclude epitopes suggested to 
be associated with adverse side effects such as 
induction of graft versus host-like diseases 
{Habeshaw et al., 1992), antibodies enhancing 
the infection of C D 4 + cells by H I V {Robinson 
et al., 1990) or gpl20 mediated apoptosis 
{Gougeon et al., 1993). Considering previous 
data on the characterization of Pr55 g* g assem-
bly domains {v. Poblotzki et al., 1993; Niedrig 
et al., 1994) careful deletion analysis within 
Pr55 g* g revealed two domains located within 
p24CA (aa 211-241) and within the p6LI 
moiety (aa 436-471), which are dispensable 
for the assembly of the mutants to premature 
V L P {Wagner et al., 1994). Consequently we 
inserted the gpl20 principal neutralizing de-
terminant V3 as a model epitope into these 
susceptible sites of the Pr55g*g-deletion con-
structs or fused this domain to the carboxyl-
terminus of the complete precursor protein 
(Fig. 2). For initial immunological studies, 
these constructs have been expressed by re-
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Fig. 2: Schematic drawing of the mutant Pr55g*g polypeptides. (A) Deleted amino acids are indicated by open boxes. The 
associated numbers represent the stretch of deleted amino acids relative to the sequence of the complete HTV-l]^/^Pr55gag 
precursor. A carboxv-terminal fusion peptide is indicated as a black box. The wt-Pr55g*g precursor is shown as a refer-
ence. The total number of amino acids of the mutant Pr55g*g polypeptides are given in italic letters. The correct designa-
tion of the mutant vaccinia viruses (V-) is given at the right. (B) Three domains derived from reading frames other than 
Pr55gag were either inserted into the mutant gag polypeptides (Pr55Al-A3) to replace the deleted sequences or fused to 
mutant Pr55F4 to generate carboxy-terminal fusionproteins. V3c: composite sequence based on a subset of sequences of 
the HIV-1 epl20 major neutralizing epitope V3. The complete amino acid sequence of the V3 epitope is shown at the left 
side of the figure, respectively. 
combinant vaccinia viruses in mammalian 
cells. For large scale purification of chimeric 
V L P , recombinant baculoviruses were estab-
lished. After infection of insect cells with the 
recombinant baculoviruses, chimeric V L P re-
sembling immature virions could be readily 
rescued and purified from the cell culture su-
pernatants in good purity and yields ranging 
from 5-20 mg/1 depending on the position and 
epitope integrated (Table 1) (Wolf et al., 1994). 
Table 1 Formation of chimeric HIV-1 Pr555a<W3 VLP 
[P9]p24 
fl-f20a 
[pg]24 
f11-f13a 
f 1 1 - f 1 3 x 1 0 0 b fl-f20 b 
p55 2.192 1.662 75.8 
P55V3-1 95 30 31.6 
P55V3-2 840 490 58.3 
P55V3-3 1.276 810 63.5 
p55V3-4 1.275 870 68.2 
a [pg] p24 from supernatants of 107 SW480 cells 2 days p.i. with 
the indicated recombinant vaccinia viruses (Abbott, p24 sandwich 
assay). The total amounts of the antigens in the fractions 1 -20 
(f1-f20) and in the antigenic peak fractions (f11 -f13) are given. 
b [pg] p24 (f11-f13) in relation to the total amount of p24 antigen 
(f1-f20). 
Recombinant vaccinia viruses expressing 
Pr55gag/V3 chimeric polypeptides induce V3-
specific CTLs in vivo 
The H I V - 1 Pr55 g* g precursor itself, which has 
been described above as a basic component for 
the presentation of immunologically relevant 
cell epitopes from recombinant V L P s has been 
repeatedly demonstrated to be an important 
target of the cell mediated immune response. 
However, the suggested importance of a C T L 
response prompted us to investigate, whether 
Pr55 g* g chimeric antigens could also induce 
C T L responses to epitopes inserted into or 
fused to the g^g-precursor. One critical aspect 
in the induction of class I restricted, C D 8 + 
C T L s by chimeric antigens is, whether altered 
flanking sequences or changes in the local con-
formation at an antigenic site might codeter-
mine processing and presentation of a translo-
cated epitope. In order to adress this question 
B A L B / c mice were immunized with recom-
binant vaccinia viruses expressing the Pr55 g* g/ 
V3 chimeric polypeptides described above, 
whereas a consensus sequence of the V3-do-
main is located at different positions within 
the Pr55g*g-precursor (v-Pr55 g * g /V3-l, - 2 , - 3 ; 
108 PFU/mouse) (Wagner et al., 1992b). The 
ability of the V3 domain to generate C T L s , not 
only in humans but in B A L B / c mice allowed a 
rapid evaluation of Pr55g*g/V3 chimeric anti-
gens in a convenient animal model (Takahashi 
et al., 1988). Syngenic P815 target cells were 
used for a 5 days in vitro restimulation of the 
isolated splenocytes and as targets in a 3 h 
cytolytic assay. In a first set of experiments 
(Fig. 3A) splenocytes of BALB/c mice (H-2 d ) 
were restimulated in vitro by syngenic targets 
treated with a 16mer V3 peptide (V3c-16; 
R I R I G P G R A F V T I G K I ) . Restimulated effec-
tor cells were tested for cytolytic activity 
against P815 cells pulsed with the indicated 
peptides. Lysis of target cells was observed ir-
relevant of whether the homologous 16mer 
V3c-peptide (V3c-16; R I R I G P G R A F V T I G K I ) 
or the heterologous V3LArpeptide (V3LAI~16; 
R I Q R G P G R A F V T I G K I ) was used for the 
precoating of target cells (1 \xM). Splenocytes, 
which were not restimulated in vitro did not 
recognize target cells following incubation 
with peptide V3c-16, with peptide V3LAI-16 or 
a control peptide (not shown). 
In order to compare processing and presenta-
tion of the V3-antigenic peptide from the 
above described Pr55g*g/V3 chimeric proteins 
to that of the original g p l 2 0 L A i external glyco-
protein, splenocytes of in vivo primed BALB/c 
mice were stimulated in vitro by P815 cells 
pulsed with peptide V3c-16 and an irrelevant 
peptide nef-16 (Fig. 3B). Target cells were in -
fected with the chimeric Pr55g*g/V3 vaccinia 
viruses, with v -gpl20LAi and, for control, with 
v-Pr55 g* g and wild type vaccinia virus (v-WT). 
Placing the V3 epitope in different positions in 
the chimeric proteins in this study did not lead 
to significant differences in the efficiency of 
recognition of the V3-epitope by specific 
C T L s if compared to authentic gpl20 L Ai-
Treatment of the C T L effector cells with anti-
lyt 2 monoclonal antibody plus rabbit comple-
ment, but not anti-L3T4 antibody plus com-
plement or complement alone led to a loss of 
killine activity in all cases tested confirming 
previous data (Takahashi et al., 1988). This 
demonstrates, that the effector cells recogniz-
ing and killing Pr55/V3-1, - 2 , or -3 and 
gpl20 expressing targets as well as V3-pep-
tide pulsed target cells are conventional 
Lyt2 + L3T4" ( C D 8 + C D 4 " ) C T L (data not 
shown). 
These results demonstrate that a selected do-
main (V3), known to include a C T L epitope, 
can replace different regions within an anti-
genic carrier protein (Pr55g*g) without signifi-
cant loss of biological activity (Wagner et al., 
1993). 
Induction of a strong CTL response by 
chimeric VLPs 
According to new results it seems to be pos-
sible to induce C D 8 + C T L s by exogenously 
applied lipoprotein particles, lipoproteines or 
liposome mediated protein transfer. Therefore 
we tested the capacity of chimeric Pr55g*g/V3 
V L P to induce a V3-specific C D 8 + C T L re-
sponse. Therefore different V L P preparations 
were injected either intraperitoneally (IP), 
subcutaneously (SC) and intravenously (IV) 
into BALB/c mice. Five days post immuniza-
tion, spleen cells from primed mice were trans-
ferred into culture and restimulated with V3 
peptide-labelled syngenic P815 cells in a 5 day 
mixed lymphocyte-tumor cell culture 
( M L T C ) . After the 5 days in vitro restimula-
tion, effector cells were tested for specific cy-
totoxic activity. Target cells in the standard 
5 1 C r release assay were again syngeneous A20 
or P815 cells labelled with a 16mer V3 consen-
sus peptide ( R I R I G P G R A F V T I G K I ) previ-
ously demonstrated to be recognized by V3 
specific C T L (Wagner et al., 1992b). The in-
duction of V3-specific C T L s strictly depend-
ed on the dose of administered antigen ranging 
from 20 fxg to 100 ng, which was still considered 
positive. The route of adminstration whether 
IP, SC or IV did not influence the C T L reacti-
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Fig. 3: (A) Induction of V3LAI~ and V3c specific cytolytic T-lymphocytes after immunization of BALB/c mice with the 
indicated recombinant vaccinia viruses. Splenocytes were isolated 2 months after immunization with 10 8 PFU/mouse of 
the indicated recombinant vaccinia viruses and restimulated for 1 week in vitro using syngenic target cells precoated with 
peptide V3c-16 (1 uM; right panel). Percent specific lysis using different ratios effector: target cells (E:T) was determined 
in a 3 h cytolytic assay after pretreatment of the targets with peptides V3c-16 (RIRIGPGRAFVTIGKI) and V3L Ai-16 
(RIQRGPGRAFVTIGKI). For control target cells were treated by irrelevant peptides as shown here for peptide nef-16. 
(B): V3-specific splenocytes were generated by in vivo immunization of BALB/c mice with the indicated vaccinia 
viruses. The effector cells were restimulated in vitro by syngenic target cells pulsed with peptide V3c-16 and tested in a 
3 h cytolytic assay. For this purpose, P815 target cells were infected by the recombinant vaccinia viruses v-Pr55V3c-l, 
v-Pr55V3c-2, and v-Pr55V3c-3 and for control by v-gpl20, v-Pr55g*g and wild type vaccinia virus (vWT). The effector: 
target ratios (E:T) are indicated. Symbols representing synthetic peptides or recombinant vaccinia viruses are given at the 
left side of the figure in the legends. The percent of specific 5 1 C r release achieved for the indicated E :T ratios was calculat-
ed as 100 x ((experimental release - spontaneous release)/(maximum release - spontaneous release)). Maximum release 
was determinated from supernatants of cells that were lysed by the addition of 5% Triton X-100. Spontaneous release was 
determined from target cells prepared as described above and incubated without added effector cells. Spontaneous release 
was below 10% in all experiments. Standard errors of the means of triplicate cultures were always less than 4% of the 
vity. V3 specific C T L s were not only found in 
splenocytes, but in lymphnodes when tested. 
Immunization of B A L B / c mice with naked 
Pr55 g* g/V3 V L P efficiently primed the C T L 
response in absence of adjuvant or replicating 
vector (69% specific lysis). In contrast V L P 
adsorbed to alum or emulsified in I F A only 
weakly stimulated a C T L response (24%, 37% 
specific lysis) (Fig. 4). A s demonstrated above 
for different types of Pr55g*g/V3 recombinant 
vaccinia viruses, the position of the V3-do-
main within different variants of chimeric 
V L P (Pr55g"g/V3-3, Pr55g*g/V3-4, Pr55 g" g/V3-
5) did not influence the induction of a V 3 -
specific C T L response. In comparison only 
weak priming of C T L was detected for in vivo 
priming with recombinant gpl60. Immunisa-
tion of Pr55 g* g V L P or V3-16mer peptide was 
not sufficient for priming a specific C T L 
response (Fig. 5). These data clearly demon-
strate that recombinant chimeric V L P repre-
sent useful tools for inducing a strong, specific 
C D 8 V C T L response in vivo in addition to a 
humoral immunity. 
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Fig. 4: Purified V L P Pr55g*g/V3-3) were administered to BALB/c mice either in absence of adjuvant (•, •), or in 
presence of IFA (•, O) or alum (open/closed triangles) as adjuvant. Splenocytes were harvested after 14 days and treated 
as described above. The generated effector cells were tested in a 5 1 Cr release assay using V3-16mer-peptide pulsed syn-
genic A20 cells (closed symbols) or untreated cells (open symbol) as targets. Different effector (E)/target ratios (T) used 
are indicated. The percentage of specific lysis was calculated as described above. 
VLP presenting various derivatives of the 
gpl20 external glycoprotein 
Recently the induction of antibodies has been 
proven for H I V patients as well as for immu-
nized chimpanzees neutralizing a variety of 
different H I V strains by recognizing conserv-
ed conformations within the gpl20 external 
glycoprotein (Steimer et al., 1991). In order to 
be capable of inducing this antibody popula-
tion we established a novel approach, which 
allows stable and covalent anchoring of gpl20 
or derivatives thereoff on the surface of the re-
combinant H I V - 1 virus-like particles by a hete-
rologous transmembrane (TM)-region. Using 
this strategy well documented side effects as-
sociated with the gp41 transmembrane protein 
can be excluded. To allow stable presentation 
of H I V - 1 gpl20 epitopes in a correct, immu-
nologically relevant conformation, we con-
structed recombinant baculoviruses express-
ing chimeric gpl20 derivatives, which are co-
valently linked via their C O O H - t e r m i n i to a 
heterologous type-1 transmembrane moiety 
(TM) of the Epstein-Barr-virus (EBV) gp250/ 
350. Both domains are seperated by a flexible 
(gly/ser)3 hinge region to allow independent 
folding of both domains. To avoid either un-
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Fig. 5: BALB/cJ mice (H-2d) were either not primed (A) or primed by a single injection of either 50 ug of V3-16mer pep-
tide (B), or 6 fig of the indicated chimeric V P L (Pr55g4g; Pr55**W3-3 to V3-5) ( O F ) , in absence of adjuvants. Lymphoid 
cells were prepared from immunised mice 6 days post immunisation and cocultivated with syngenic V3-16mer peptide 
labelled syngenic P815 cells, irradiated with 20000rad. A control group included unprimed BALB/c cells stimulated in 
vitro with V3- 16mer peptide labelled P815 cells. Cytotoxic effector cell populations were harvested after 5 days of in vitro 
culture. The cytotoxic response was determined against the syngenic target cell line A20 pulsed for lh with 10"8M 
V3-16mer peptide (closed symbols). Negative controls were not pulsed target A20 cells in a standard 5 1 Cr release test 
(open symbols). 
specific cleavage of the gpl20 at carboxytermi-
nal cleavage sites or uncorrect folding of the 
e^-chimeras, we additionally established de-
rivatives truncated from the COOH-terminus 
by either five (gpl20/5") or 20 amino acids 
(gp120/20"), linked to the T M . The chimeric 
proteins were produced in insect cells using 
the baculovirus expression system. A recom-
binant baculovirus expressing the complete 
gpl60 H I V - 1 envelope protein was construct-
ed as a positive control (Fig. 6). Surface expres-
sion of the produced H I V - 1 gpl20/TM chime-
ric glycoproteins on infected insect cells has 
been proven by APAAP-immunostaining. 
H i g h affinity recognition by a pannel of differ-
ent conformation dependent monoclonal anti-
bodies (Mab) revealed a correct folding of all 
proteins presented on the cell surface. In order 
to produce H I V - 1 Pr55 g* g V L P carrying stably 
anchored gpl20 on their surface we coinfected 
insect cells with Pr55 g* g and gpl60 or various 
gpl20/TM recombinant baculoviruses. Ultra-
thin sections of insect cells coexpressing 
Pr55 g* g and the gpl20 derivatives (gpl20/TM, 
gpl20/5"TM, gpl20/20"TM, gpl60) revealed 
efficient budding of recombinant V L P . Har-
vested cell culture supernatants were analyzed 
by sucrose sedimentation gradients revealing 
almost identical yields of recombinant V L P 
for all coinfections tested. The antigenic peaks 
were detected at the expected sucrose density 
of 1.15-1.18 g/cm3. The peak fractions were 
analyzed by immunoblotting using a panel of 
different Pr55 g* g, gpl20 or gp41 specific mon-
oclonal antibodies recognizing the particulate 
carrier in addition to the presented gpl20 or 
160 glycoproteins. A l l tested peak fractions 
demonstrated the Pr55 g* g carrier as well as the 
expected glycoprotein derivative (will be pub-
lished elsewhere). 
To study the capability of the chimeric gag/ 
env V L P to induce cytotoxic T-lymphocytes in 
vivo, BALB/c mice were immunized with the 
different gag/env hybrid V L P , again in com-
plete absence of adjuvants or replicating vector 
(Fig. 7). For control B A L B / c mice were inject-
ed with V3-peptide ( R I Q R G P G R A F V T I G -
KI) , purified gpl60 or H I V Pr55 g* g V L P only. 
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Fig. 6: Construction of chimeric glycoprotein mutants. The wild-type glycoprotein precursor gpl60 is diagrammed at the 
top of the figure. The HIV-1 gp41 transmembrane domain of the gpl60 was replaced by a heterologous Epstein Barr V i -
rus (EBV) type 1 transmembrane domain (TM) (53aa), which was linked to the COOH-terminal end of the gpl20 by a 
flexible gly/ser (6aa) stretch (gpl20TM). Additionally we evaluated two truncated derivatives lacking 5 (gpl20/5"TM) or 
20 amino acids (gpl20/20~TM) at the COOH.-terminus of the gpl20TM construct, respectively. 
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Fig. 7: Recombinant PrSyVenv VLP, but not HIV-1 V3-loop derived peptides primed V3-specific C T L from BALB/c 
mice. BALB/cJ mice (H-2d) were primed in vitro by a single injection of either 6 ng of different preparations of chimeric 
gag/env V L P (D-G), 6 Lig Pr55g** V L P (C), 50 |ig of a 16mer V3-peptide (B) in absence of adjuvants. Negative controles 
were not primed B A L B / C mice (A). The in vitro restimulation of C T L and cytotoxity assay was carried out as descriped 
above. 
A s described above, neither the synthetic V 3 -
peptide nor Pr55 g* g V L P were sufficient to 
prime an adequate V3-specific C T L response. 
A comparably weak C T L response could be 
demonstrated after administration of purified 
gpl60 (Fig. 7). These data clearly indicate, that 
anchoring of gpl60 or derivatives thereoff on 
the surface of recombinant Pr55 g* g V L P s re-
sults in a favourable antigen presentation, 
which is capable of inducing a highly efficient 
C T L response to the presented membrane 
proteins. 
Conclusion 
With respect to a rational vaccine design there 
is ample evidence that cell mediated rather 
than humoral immunity plays a crucial role in 
the control of virus replication and the pro-
gression to the symptomatic state of disease. 
We have constructed a novel per se highly im-
munogenic antigen presentation system allow-
ing the presentation of (i) either selected, im-
munologically relevant epitopes or (ii) of deri-
vatives of the complete external glycoprotein 
by noninfectious, recombinant Vx55m V L P . 
Immunological analysis revealed both, the in-
duction of a humoral {Wolf et al., 1994) in addi-
tion to a cell mediated immunity in complete 
absence of adjuvants. Studies analyzing the 
safety, immunogenicity and efficacy of the 
presented candidate vaccines in primates are in 
progress. 
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